Clinical Trial Update: Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma [Phase 1]

View source ↗

Summary

Phase 1 safety study of the GVAX melanoma vaccine with or without cyclophosphamide for patients with surgically resected melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• GVAX

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Melanoma | Phase 1 | Status: COMPLETED